...reasons. Olympus Biotech will discontinue its osteoinductive and osteoconductive bone graft materials OP-1 PUTTY and OPI-1...

...have included cancer play OPi S.A. and endoscopic tool manufacturer Mauna Kea Technologies S.A. (Euronext:MKEA). OPi...

...Financial terms were not disclosed. EUSA acquired both programs as part of its acquisition of OPi...

...& Co. KG (Marburg, Germany) holds marketing rights to Nitoman in Germany and Austria, and OPi...

...Alize Pharma S.A.S. , Lyon, France Business: Endocrine Appointed: Gilles Alberici, former president of OPi S.A. WIR...

...the $175 million that went to specialty pharma EUSA for the acquisition of oncology company OPi...

...EUSA : a $175 million B round to fund its acquisition of orphan drug specialist OPi...

...South Africa, New Zealand and Australia. Temmler has marketing rights in Germany and Austria, while OPi...

...acquired OPi for more than E100 million ($131.7 million). The exact sum was not disclosed. OPi...
...leukemia (ALL). The company posted 2006 sales of $23 million. Further terms were not disclosed. OPi...
...and CEO Gilles Alberici joined EUSA's board. EUSA Pharma Inc. , King of Prussia, Penn. OPi...

...came from specialty pharma EUSA , which raised $175 million to acquire French oncology-focused company OPi...